compounded semaglutide impurities safety risks Novo Nordisk calls out dangers of GLP-1s in new ad Evaluating Risk When Prescribing Compounded

Semaglutide withdrawal symptoms extend beyond simple weight regain, with many patients reporting a return of intense food cravings and appetite increases that feel overwhelming after months of suppressed hunger

Meet the Team Dr

DVT events were captured as part of general safety monitoring, but the trial was not powered to detect meaningful differences in such a rare outcome

Limited data exists on this approach with Retatrutide specifically

These data are important for a full understanding of the drug's benefitrisk profile and will be central to any future regulatory assessment

When we talk about boosting or activating GLP-1, we mean increasing the levels of this hormone to enhance its effects on metabolism, insulin regulation, and appetite suppression. This is what GLP-1 medications do